TP-102 clinical trial presented at ECCMID 2023

Last month Technophage team attended 33rd European Congress of Clinical Microbiology & Infectious Diseases with the clinical team from Israel, and Dr. Ran Nir-Paz from Hadassah Medical Center, presented the results obtained in the Phase I/IIa double-blinded, randomized, placebo-controlled two-part, multicenter study, aimed to determine the safety and tolerability of multiple doses of TP-102 in subjects with uninfected and infected diabetic foot ulcers. Overall, no treatment related adverse events associated to TP-102 or placebo were reported during the trial in both cohorts. The safety and tolerability of TP-102 following topical administration of multiple doses to diabetic patients with uninfected and infected diabetic foot ulcers was confirmed. Preliminary data suggests that innovative bacteriophage therapy TP-102 may be effective in reduction of diabetic foot ulcers volume. TP-102 is being developed for the treatment of infected diabetic foot ulcers caused by Pseudomonas aeruginosa , Acinetobacter baumannii and Staphylococcus aureus ; phase I/IIa has been successfully concluded and the company is now preparing the next clinical phases.

The release as fetched from its publisher. technophage.pt ↗